Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the results of a Phase Ib study evaluating tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanoma (NCT02535078). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.